Replies to post #97961 on Biotech Values

[DewDiligence]

This is ADA’s PR about the latest Avandia study that found no incremental CV risk relative to placebo:

http://finance.yahoo.com/news/Diabetes-Drug-Rosiglitazone-iw-794534582.html?x=0&.v=1